DexCom, Inc. (NASDAQ:DXCM) – Analysts at William Blair increased their Q4 2017 EPS estimates for shares of DexCom in a research note issued on Tuesday. William Blair analyst M. Kaczor now expects that the medical device company will earn $0.06 per share for the quarter, up from their prior estimate of $0.02. William Blair also issued estimates for DexCom’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.08) EPS and FY2018 earnings at ($0.56) EPS.

Several other analysts also recently commented on DXCM. Barclays restated a “hold” rating and set a $60.00 target price on shares of DexCom in a report on Monday. Piper Jaffray Companies restated a “buy” rating and set a $87.00 target price on shares of DexCom in a report on Thursday, September 28th. Northland Securities assumed coverage on shares of DexCom in a report on Tuesday, September 26th. They set an “outperform” rating and a $85.00 target price on the stock. Leerink Swann restated a “buy” rating and set a $57.00 target price (down from $85.00) on shares of DexCom in a report on Friday, September 29th. Finally, Oppenheimer dropped their target price on shares of DexCom from $92.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, September 28th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. DexCom currently has a consensus rating of “Buy” and a consensus price target of $72.31.

DexCom (NASDAQ:DXCM) opened at $58.60 on Thursday. DexCom has a one year low of $42.62 and a one year high of $88.80. The firm has a market cap of $5,090.00, a P/E ratio of -102.81 and a beta of 0.31. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

In other DexCom news, Director Steven R. Altman acquired 10,000 shares of the stock in a transaction dated Monday, November 6th. The shares were bought at an average cost of $49.61 per share, for a total transaction of $496,100.00. Following the completion of the acquisition, the director now directly owns 4,353 shares of the company’s stock, valued at $215,952.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 12,000 shares of DexCom stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $55.00, for a total transaction of $660,000.00. The disclosure for this sale can be found here. Insiders sold 38,140 shares of company stock worth $2,158,576 over the last quarter. 1.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. AXA increased its holdings in DexCom by 10.5% during the third quarter. AXA now owns 1,318,931 shares of the medical device company’s stock worth $64,529,000 after buying an additional 124,920 shares during the last quarter. DF Dent & Co. Inc. increased its holdings in DexCom by 438.2% during the third quarter. DF Dent & Co. Inc. now owns 75,856 shares of the medical device company’s stock worth $3,711,000 after buying an additional 61,762 shares during the last quarter. Neuberger Berman Group LLC increased its holdings in DexCom by 54.7% during the third quarter. Neuberger Berman Group LLC now owns 385,421 shares of the medical device company’s stock worth $18,857,000 after buying an additional 136,205 shares during the last quarter. California Public Employees Retirement System increased its holdings in DexCom by 2.0% during the third quarter. California Public Employees Retirement System now owns 129,400 shares of the medical device company’s stock worth $6,331,000 after buying an additional 2,500 shares during the last quarter. Finally, Sessa Capital IM L.P. acquired a new position in DexCom during the third quarter worth $14,678,000.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/equities-analysts-issue-forecasts-for-dexcom-inc-s-q4-2017-earnings-dxcm/1802815.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.